Fruquintinib as Maintenance Therapy for Advanced Colorectal Cancer After Adjuvant Chemotherapy: A Clinical Trial

This clinical trial investigates the effectiveness and safety of fruquintinib as a maintenance treatment for patients with advanced colorectal cancer (CRC) who have achieved no evidence of disease (NED) after completing adjuvant chemotherapy. Despite surgery and adjuvant therapy, the 5-year survival rate for patients with colorectal liver metastases (CRLM) remains below 20%, with a high recurrence rate exceeding 60%. This highlights an urgent need for effective maintenance therapies to improve long-term outcomes.

Fruquintinib, a highly selective anti-angiogenesis inhibitor, has demonstrated promising anti-tumor activity with a manageable safety profile in previous studies. The Chinese Society of Clinical Oncology (CSCO) guidelines have included fruquintinib as a first-line treatment recommendation for CRC. This trial aims to evaluate whether fruquintinib maintenance therapy, following adjuvant chemotherapy, can reduce the risk of recurrence and prolong the time to recurrence and metastasis in patients with advanced CRC who have achieved NED. The study will provide valuable data on the efficacy and safety of fruquintinib in this setting and may contribute to improved treatment strategies for advanced CRC.